Cambridge Research Biochemicals releases new DISCOVERY Antibodies catalogue

Published: 22-Feb-2017
Ingredients

CRB's new product range will offer the same antibodies that CRB usually offers and includes targets suggested by customers, as well as complex, rare and post translational modification specific custom-made antibodies

Each month, new product lines are being added to supplement the selection in place and antigen peptides synthesised in-house are also available to purchase.

In addition to the brand new DISCOVERY Antibodies website with e-commerce functionalities and analytical data, CRB is redesigning its existing website to improve user experience.

CRB also launched a peptides counterpart to DISCOVERY Antibodies in 2016 – DISCOVERY Peptides. The site features a selection of popular peptide candidates all synthesised at CRB’s Teesside premises.

Emily Humphrys, CRB’s Commercial Director, said: “We felt that since the article, ‘Reproducibility Crisis: Blame it on the Antibodies,’ in Nature News (2015), this was the perfect time for a more discerning player to enter the market.”

“As we manufacture all of the peptides and antibodies marketed through the new catalogues ourselves, we can be sure that the products are of the very best quality and the highest purity.”

  • Companies:
  • Cambridge Research Biochemicals
See more

You may also like

Ingredients

CRB signs distribution deal for generic and click reactive dyes

Read more
The agreement also affords CRB increased flexibility to offer larger quantities of labelled peptides at a more affordable price, the company says

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

CRB signs distribution deal for generic and click reactive dyes

The agreement also affords CRB increased flexibility to offer larger quantities of labelled peptides at a more affordable price, the company says
Ingredients

Cambridge Research Biochemicals expands peptide capacity

First firm in Europe to acquire powerful Overture synthesiser, which upgrades the Cleveland firm\'s peptide manufacturing capacity
Ingredients

Cambridge Research Biochemicals wins supply contract

The UK-based research peptide manufacturer has been appointed a key supplier to RCUK SSC
Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

The company will exhibit its omega-3 ingredient, as well as its active gut health solution
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Subscribe now